Skip to main content

Raxibacumab

Approval date: December 14, 2012
Company: GlaxoSmithKline
Treatment for: Inhalational Anthrax

Medically reviewed by Drugs.com. Last updated on Sep 5, 2024.

FDA Approves Raxibacumab

The U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

What is Raxibacumab?

Before you receive Raxibacumab

Before you receive raxibacumab, tell your healthcare provider about all of your medical conditions, including if you are:

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

How will I receive Raxibacumab?

amoxicillin, doxycycline, ciprofloxacin, levofloxacin, Levaquin

Raxibacumab side effects

Raxibacumab may cause serious side effects, including:

The most common side effects of Raxibacumab include rash, pain in your arms or legs, itchiness, and sleepiness.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of raxibacumab. For more information, ask your healthcare provider.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.

General information about the safe and effective use of Raxibacumab

This patient information leaflet summarizes the most important information about Raxibacumab. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about Raxibacumab that is written for health professionals.

What are the ingredients in Raxibacumab?

Active ingredient: raxibacumab

Inactive ingredients: citric acid, glycine, polysorbate 80, sodium citrate, and sucrose

Raxibacumab Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for raxibacumab.

(raxibacumab) - Emergent Manufacturing Operations Baltimore LLC
Formulation type Strength
Single-Dose Vial 1,700 mg/34 mL (50 mg/mL)

More about raxibacumab

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.